Third Rock Ventures V, L.P. 4

What Happened
Third Rock Ventures V, L.P. (a reported >10% holder) sold 133,618 shares of Rapport Therapeutics (RAPP) in an open-market/private sale on May 11, 2026. The weighted-average price was $40.24 per share, producing proceeds of approximately $5,377,323. This transaction was a sale (routine disposition by an institutional holder), not a purchase.

Key Details

• Transaction date: 2026-05-11; Filing date: 2026-05-13 (appears timely — within two business days).
• Price: weighted average $40.24; individual sale prices ranged from $40.00 to $40.665 (report offers to provide per-price breakdown on request).
• Shares sold: 133,618; proceeds ~ $5.38 million.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: transaction executed under a Rule 10b5-1 trading plan dated Nov 21, 2025 (F1); weighted-price range disclosed with offer to provide further breakdown (F2); filing includes customary beneficial-ownership disclaimers for TRV entities (F3, F4).
• Nature of filer: Institutional/venture investor (10% owner), not company management or director.

Context
This was an institutional sale executed under a pre-established 10b5-1 plan, which typically indicates pre-set selling instructions rather than ad-hoc insider trading. The filing includes standard partnership disclaimers about beneficial ownership among related Third Rock entities; treat this as VC/investor liquidity rather than a direct signal from company executives.